Cutting Edge: Core Binding Factor β Is Required for Group 2 Innate Lymphoid Cell Activation.
Xiaofei ShenMingwei LiangXiangyu ChenMuhammad Asghar PashaShanti S D'SouzaKelsi HiddeJennifer HowardDil Afroz SultanaIvan Ting Hin FungLongyun YeJiexue PanGang LiuJames R DrakeLisa A DrakeJinfang ZhuAvinash BhandoolaQi YangPublished in: Journal of immunology (Baltimore, Md. : 1950) (2019)
Group 2 innate lymphoid cells (ILC2) are tissue-resident, long-lived innate effector cells implicated in allergy and asthma. Upon activation, mature ILC2 rapidly secrete large amounts of type-2 cytokines and other effector molecules. The molecular pathways that drive ILC2 activation are not well understood. In this study, we report that the transcriptional controller core binding factor β (CBFβ) is required for ILC2 activation. Deletion or inhibition of CBFβ did not impair the maintenance of ILC2 at homeostasis but abolished ILC2 activation during allergic airway inflammation. Treatment with CBFβ inhibitors prevented ILC2-mediated airway hyperresponsiveness in a mouse model of acute Alternaria allergen inhalation. CBFβ promoted expression of key ILC2 genes at both transcriptional and translational levels. CBF transcriptional complex directly bound to Il13 and Vegfa promoters and enhancers, and controlled gene transcription. CBFβ further promoted ribosome biogenesis and enhanced gene translation in activated ILC2. Together, these data establish an essential role for CBFβ in ILC2 activation.
Keyphrases
- nk cells
- mouse model
- transcription factor
- gene expression
- induced apoptosis
- genome wide
- poor prognosis
- stem cells
- copy number
- cell cycle arrest
- mesenchymal stem cells
- cell death
- dendritic cells
- liver failure
- allergic rhinitis
- dna methylation
- heat shock protein
- electronic health record
- long non coding rna
- deep learning
- cystic fibrosis
- data analysis
- artificial intelligence
- infectious diseases